Heterocycles of biological importance. Part 6.1. The formation of novel biologically active pyrimido[1,2-a]benzimidazoles from electron deficient alkynes and 2-aminobenzimidazoles

Helene Wahe\textsuperscript{a,b}, Peter F. Asobo\textsuperscript{b}, Rafael A. Cherkasov\textsuperscript{a}, Augustin E. Nkengfack\textsuperscript{b}, Gabriel N. Folefoc\textsuperscript{b}, Zacharias T. Fomum\textsuperscript{b}, and Dietrich Doepp\textsuperscript{c}\textsuperscript{*}

\textsuperscript{a}Department of Chemistry, Kazan State University, Kremlovskaya str. 18, Kazan 480008, Russia \textsuperscript{b}Department of Organic Chemistry, University of Yaounde, P. O. Box 812, Yaounde, Cameroon, and \textsuperscript{c}Institut fuer Chemie, Universitaet Duisburg -Essen, D-47048 Duisburg, Germany

E-mail: doepp@uni-duisburg.de

Dedicated to Professor Branko Stanovnik on his 65\textsuperscript{th} birthday

(received 11 Sep 03; accepted 04 Dec 03; published on the web 29 Dec 03)

Abstract

2-Aminobenzimidazole (1a) and its 5,6-dimethyl derivative 1b react with phenylpropynenitrile (2) to give 2-amino-4-phenylpyrimido[1,2-a]benzimidazoles 8a,b in excellent yields. Of these compounds, 2-amino-7,8-dimethyl-4-phenylpyrimido[1,2-a]benzimidazole (8b) has been shown to possess diuretic properties. Acetylenic aldehydes 9a,b also react with 1a,b to give pyrimido[1,2-a]benzimidazoles 13a-13d in good yield.

Keywords: 2-Aminobenzimidazole, pyrimido[1,2-a]benzimidazole, Michael addition, diuretic

Introduction

The usefulness of allenic and acetylenic nitriles as starting materials in heterocyclic syntheses has been amply demonstrated\textsuperscript{2-12}. Recently, we have synthesized pyrimido[1,2-a]benzimidazoles from allenic nitriles and 2-aminobenzimidazoles and shown that such heterocycles are of great potential interest\textsuperscript{1}. We now report that pyrimido[1,2-a]benzimidazoles are formed similarly from the reaction of acetylenic nitriles and acetylenic aldehydes with 2-aminobenzimidazoles.

Results and Discussion
When 3-phenylpropynenitrile (2) was allowed to react with 2-aminobenzimidazole (1a) and its 5,6-dimethyl derivative 1b, we found that 2-amino-4-phenylpyrimido[1,2-a]benzimidazoles 8a,b were obtained in high yield. The reaction of 2 and the benzimidazoles very likely proceeds by initial attack of the imino ring nitrogen of the benzimidazole to the acetylenic β-carbon, followed by cyclisation to give compounds 8 (Scheme 1).

![Scheme 1](image)

1,6-8: a: R¹ = R² = H; b: R¹ = R² = CH₃

There is no indication whatsoever of initial attack of the 2-amino group of 1a,b on C-3 of 2. When 5,6-dimethyl substituted benzimidazole 1b was used, a solid product 8b precipitated from the reaction mixture immediately at reflux in N,N-dimethylformamide as solvent. This indicated that the conjugate addition is the rate determining step in pyrimidobenzimidazole formation, and cyclisation takes place immediately to give compound 8b which precipitated from the reaction mixture.

The IR, ¹H NMR, ¹³C NMR and the mass spectral data of the products are consistent with the structures assigned to 8a,b. These products showed twin stretching bands in the IR spectra at 3440, 3301 and 3442, 3303 cm⁻¹ for NH₂ as well as intense stretching bands for C=N between 1653-1650 cm⁻¹ and for C=C at 1600 cm⁻¹.

The NMR spectra of 8a,b showed signals for two shielded aryl-protons each, one of which gives rise to a sharp singlet at δ = 6.15 ppm (8a) and 6.10 ppm (8b) and is attributed to 3-H. The other one, which appears as a multiplet at δ 6.13 ppm (for 8a) and as a singlet at δ 5.87 ppm in the 7,8-dimethyl compound 8b, is attributed to 6-H.

The shielding effect observed for 6-H is most likely due to the anisotropy of the phenyl group attached to C-4 which cannot be coplanar with the molecular skeleton and therefore exerts an
upfield shift on 6-H. The same effect has been observed also by Al-Jallo and others\textsuperscript{13} for related systems.

The \textsuperscript{13}C-NMR-spectra of 8\textsubscript{a,b} display two low-field signals for C-2 (\(\delta = 153.6\) for 8\textsubscript{a} and 153.5 for 8\textsubscript{b}) and the guanidine-like carbon C-10a (\(\delta = 160.5\) for 8\textsubscript{a} and 161.5 for 8\textsubscript{b}), whereas the signals for the enamine-\(\beta\)-carbon-like C-3 are shifted upfield: \(\delta = 99.6\) (8\textsubscript{a}) and 98.9 (8\textsubscript{b}). All other carbon and proton signals fall into the expected shift ranges (see Experimental).

Similarly acetylenic aldehydes 9\textsubscript{a,b} reacted by conjugate addition to 1 giving 4-pentyl and 4-phenylpyrimido[1,2-\(a\)]benzimidazoles 13\textsubscript{a-d} by elimination of water via intermediates 10, 11, and 12 (Scheme 2).

\begin{table}[h]
\centering
\begin{tabular}{|c|c|c|c|}
\hline
   & \(R^1\) & \(R^2\) & \(R^3\) \\
\hline
a & H  & H  & Ph  \\
\hline
b & Me & Me & Ph  \\
\hline
c & H  & H  & 1-pentyl \\
\hline
d & Me & Me & 1-pentyl \\
\hline
\end{tabular}
\end{table}

\textbf{Scheme 2}

The structural assignment of 13\textsubscript{a-d} is based on the following characteristic spectral data. The \(^1\)H-NMR signals for 2-H are found at pronouncedly low field between \(\delta = 8.56\) and 8.80 ppm as expected, whereas 3-H gives rise to resonances between 6.60 and 6.98 ppm. Again, the anisotropy exerted by the non-coplanar 4-phenyl group in 13\textsubscript{a,b} gives rise to significant upfield shifts for 6-H compared to 4-pentyl substitution (in 13\textsubscript{c,d}): \(\delta = 6.71\) (for 13\textsubscript{a}) and 6.43 (for 13\textsubscript{b}) in contrast to 8.16 (for 13\textsubscript{c}) and 7.76 (for 13\textsubscript{d}), respectively. The \textsuperscript{13}C-NMR spectra show signals for C-2 between 154.7 and 156.0 ppm, and for the quaternary carbon C-10a at 151.0–151.4 ppm, which is 10 ppm upfield compared to 8\textsubscript{a,b}. Again, C-3 signals are relatively upfield in the range of 105.9–108.4 ppm. All other carbon and proton chemical shifts fall into the range of expectation (see Experimental).
Biological activity of compound 8b

2-Amino-7,8-dimethyl-4-phenylpyrimido[1,2-a]benzimidazole (8b) was subjected to various biological activity tests\(^1\). It was found that it was completely non-toxic to mice at concentrations of up to 300 milligrams per kilogram by weight used in the experiment when administered orally or peritoneally. As a metabolic agent, it possesses diuretic properties.

Test 1. Acute toxicity

Mice were dosed at 300mg/kg p.o. and 200mg/kg i.p. for observation of acute toxic symptoms or autonomic effects during the subsequent 72 hours. When none were noted; pharmacological evaluation proceeded employing doses and concentrations for each test based on appropriate multiples of doses required by suitable reference compounds. When acute toxicity was observed initially, the minimal toxic dose was determined and pharmacological screening doses were reduced proportionally. Since no abnormal responses were observed for the 300mg/kg (p.o.) and 200mg/kg (i.p.) doses, the compound was regarded non-toxic.

Test 2. Diuretic properties

Rats were hydrated and given the test drug p.o., the score refers to the multiple of that day’s control sodium excretion (mceq/100g rat) produced by a test drug, e.g. if the control sodium excretion is 150 mceq (usual) and the test drug produces more than twice that amount, say 450 mceq, the score is 450/150 = 3.0 (Table 1, mceq = microgram-equivalent).

Table 1. Effect of compound 8b on the metabolic system

<table>
<thead>
<tr>
<th>No.</th>
<th>Test</th>
<th>Dose(^{[a]})</th>
<th>Criterion</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Hypocholesterolemic (mice)</td>
<td>400</td>
<td>&gt;15</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>HP-Beta-Lipoprotein (mice)</td>
<td>400</td>
<td>&gt;20</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>Hypoglycemic (mice)</td>
<td>100</td>
<td>&gt;20</td>
<td>0</td>
</tr>
<tr>
<td>4</td>
<td>Diuretic (rat)</td>
<td>20</td>
<td>&gt;2</td>
<td>3.5</td>
</tr>
<tr>
<td>5</td>
<td>Diuretic (^{[b]}) (rat)</td>
<td>10</td>
<td></td>
<td>1.2</td>
</tr>
<tr>
<td></td>
<td>“</td>
<td>20</td>
<td></td>
<td>3.6 ED(^{100})[c]</td>
</tr>
<tr>
<td></td>
<td>“</td>
<td>20</td>
<td></td>
<td>2.1 MED(^{[d]})</td>
</tr>
</tbody>
</table>

\(^{[a]}\) milligrams per kilogram of weight.

\(^{[b]}\) With reference to spironolactone (= 7α-Acetyltio-3-oxo-17 α -pregn-4-ene-21,17β-carbolactone).

\(^{[c]}\) ED\(^{100}\) = Dose which is always active in the test system.

\(^{[d]}\) MED = Minimum Effective Dose.

Experimental Section
**General Procedures.** Elemental and spectroscopic analyses were performed at Institut fuer Chemie at Universitaet Duisburg-Essen in Duisburg, Germany. Melting points were determined with a Reichert Thermovar microscope and are uncorrected. The infrared (IR) spectra (potassium bromide pellets) were measured with a Varian Cary 2290 and a Perkin-Elmer 298 spectrophotometer. The 300 MHz and 75 MHz $^{13}$C NMR spectra were performed on a Bruker WM 300 instrument with tetramethylsilane as internal standard. Mass spectra were obtained with a MAT 311A instrument using EI at 70 eV and direct inlet. Purities of the samples were checked by tlc. Alumina of activity 5 for column chromatography was prepared by mixing 15 ml of distilled water and 100g of neutral alumina which had been preheated for 4 hours at 120°C. Combustion analyses were performed with CHN elemental analyzer “Carlo Erba” Model 1106. Phenylpropynenitrile (2) was prepared as previously reported.\(^{15}\)

**Preparation of 2-amino-4-phenylpyrimido[1,2-a]benzimidazoles (8a,b).** Phenylpropynenitrile (2, 1.27g, 10 mmol) was heated under reflux with 2-aminobenzimidazole (1a, 1.33g, 10 mmol) or 5,6-dimethyl-2-aminobenzimidazole (1b, 1.61g, 10 mmol) in N,N-dimethylformamide (50 mL). A solid precipitated after 3 hours (from 2 and 1a) or immediately (from 1b and 2).

**2-Amino-4-phenylpyrimido[1,2-a]benzimidazole (8a).** Yield 1.97g (76%) of colorless crystals (DMSO), no melt below 300°C (Lit. [16]: 364-366°C); IR: $\nu$/cm$^{-1}$ 3440, 3303 (NH$_2$), 3054 (aryl C-H), 1653 (C=N), 1600 (C=C), 1533 (NH$_2$ def).

NMR data: $\delta$H (DMSO-d$_6$) 6.13 (1H, 6-H), 6.15 (1H, s, 3-H), 6.75 (1H, m, 7-H), 7.15 (1H, m, 8-H), 7.50 (1H, m, 9-H), 7.40 (2H, s, NH$_2$ deuterium exchangeable), 7.63-7.69 (5H, m, Ph). $\delta$C (DMSO-d$_6$) 99.6 (C-3), 112.5 (C-6), 117.6 (C-9), 118.7 (C-8), 123.9 (C-7), 127.7 (C-5a), 128.5 (Ph-C3, C5), 129.3 (Ph-C2, C6), 130.8 (Ph-C4), 132.6 (Ph-C1), 144.7 (C-9a), 147.7 (C-4), 153.6 (C-2), 160.5 (C-10a). MS: m/z (%) = 260 (M$^+$, 100), 259 (23), 220 (18), 133 (8), 116 (4), 104 (5), 90 (9), 77 (5). Anal. Calcd. for C$_{16}$H$_{12}$N$_4$: C, 73.85; H, 4.61; N, 21.54. Found: C, 73.41; H, 4.58; N, 21.22.

**2-Amino-7,8-dimethyl-4-phenylpyrimido[1,2-a]benzimidazole (8b).** Yield 2.50g (87%), colorless crystals (DMSO), no melt below 300°C; IR: $\nu$/cm$^{-1}$ 3442, 3301 (NH$_2$), 3050 (aryl C-H), 1650 (C=C), 1529 (NH$_2$ def).

NMR data: $\delta$H (DMSO-d$_6$) 1.95 (3H, s, 7-CH$_3$), 2.25 (3H, s, 8-CH$_3$), 5.87 (1H, s, 6-H), 6.10 (1H, s, 3-H), 7.27 (2H, s, NH$_2$ deuterium exchangeable), 7.65 (1H, s, 9-H), 7.59-7.70 (5H, m, Ph). $\delta$C (DMSO-d$_6$) 19.84 (8-CH$_3$), 20.06 (7-CH$_3$), 98.91 (C-3), 112.94 (C-6), 117.94 (C-9), 126.29 (C-7), 126.51 (C-8), 128.39 (Ph-C3, C5), 129.06 (Ph-C2, C6), 130.50 (Ph-C4), 132.61 (Ph-C1), 143.13 (C-9a), 147.50 (C-4), 153.50 (C-2), 161.5 (C-10a). MS: m/z (%) = 288 (M$^+$, 100), 287 (34), 273 (15), 160 (6), 144 (7), 136 (6), 128 (5). Anal. Calcd. for C$_{18}$H$_{16}$N$_4$: C, 73.00; H, 5.56; N, 19.44. Found: C, 74.86; H, 5.53; N, 19.15.

**4-Phenylpyrimido[1,2-a]benzimidazole (13a).** 2-Aminobenzimidazole (1a, 2.53g, 19 mmol) was heated under reflux with phenylpropargylaldehyde (9a, 2.80g, 19 mmol) in ethanol (25 mL) for 6 days. Removal of solvent gave a dark brown oil which partially solidified on standing at room temperature. Purification of 5.33g of this crude product by column chromatography on neutral alumina (300 g, activity 5) eluting with hexane/ethyl acetate (2:8) gave a crystalline
residue. Crystallization from dichloromethane/hexane gave 3.98 g (75%) of colorless crystals, mp 178–180°C; ir: ν/cm\(^{-1}\) 3047 (aryl C-H), 1622 (C=N) and 1603 (C=C). NMR data: δ\(_H\) (CDCl\(_3\)) 6.71 (1H, m, 6-H), 6.75 (1H, m, 3-H), 7.02 (1H, m, 7-H), 7.50 (1H, m, 8-H), 7.59 – 7.75 (5H, m, Ph), 8.00 (1H, m, 9-H), 8.80 (1H, m, 2-H). δ\(_C\) (CDCl\(_3\)) 108.4 (C-3), 114.7 (C-6), 119.7 (C-9), 121.1 (C-8), 125.9 (C-7), 127.1 (C-5a), 128.5 (Ph-C3, C5), 129.5 (Ph-C2, C6), 131.2 (Ph-C4), 132.2 (Ph-C1), 144.4 (C-9a), 149.6 (C-4), 151.4 (C-10a), 156.0 (C-2). MS: m/z (%) = 245 (M\(^+\), 100), 244 (65), 243 (9), 123 (7), 122 (11), 116 (3), 90 (5). Anal. Calcd. for C\(_{16}\)H\(_{11}\)N\(_3\): C, 78.35; H, 4.52; N, 17.13. Found C, 78.17; H, 4.52; N, 17.09.

7,8-Dimethyl-4-phenylpyrimido[1,2-a]benzimidazole (13b). 2-Amino-5,6-dimethylbenzimidazole (1b, 3.0 g, 19 mmol) was heated under reflux with phenylpropargylaldehyde (9a, 2.8 g, 19 mmol) in ethanol (25 mL) for 7 days. Removal of solvent gave a crude product (5.6 g) which was purified by column chromatography on neutral alumina (300 g, activity 5) eluting with ethyl acetate to give a crystalline compound which was crystallized from dichloromethane/hexane to give 3.4 g (61%) of colorless crystals, mp 178–179°C; ir: ν/cm\(^{-1}\) 3054 (aryl C-H), 2966 (aliph. C-H), 1610 (C=N), 1594 (C=C). NMR data: δ\(_H\) (CDCl\(_3\)) 2.17 (3H, s, 7-CH\(_3\)), 2.39 (3H, s, 8-CH\(_3\)), 6.43 (1H, s, 6-H), 6.71 (1H, m, 3-H), 7.59 – 7.74 (5H, m, Ph), 7.75 (1H, s, 9-H), 8.75 (1H, m, 2-H). δ\(_C\) (CDCl\(_3\)) 20.3 (8-CH\(_3\)), 20.7 (7-CH\(_3\)), 108.0 (C-3), 114.7 (C-6), 119.5 (C-9), 125.5 (C-7), 129.9 (C-8), 128.6 (Ph-C3, C5), 129.5 (Ph-C2, C6), 131.2 (Ph-C4), 132.3 (Ph-C1), 135.2 (C-5a), 143.2 (C-9a), 149.1 (C-4), 151.0 (C-10a), 155.0 (C-2). MS: m/z (%) = 273 (M\(^+\), 100), 272 (39), 270 (4), 259 (5), 258 (22), 257 (4), 256 (6), 168 (4), 143 (4), 137 (3), 129 (8), 116 (3). Anal. Calcd. for C\(_{18}\)H\(_{15}\)N\(_3\): C, 79.09; H, 5.53; N, 15.38. Found C, 79.09; H, 5.56; N, 15.31.

4-Pentylpyrimido[1,2-a]benzimidazole (13c). 2-Aminobenzimidazole (1a, 2.66 g, 20 mmol) was refluxed with oct-2-ynal (2b, 2.48 g, 20 mmol) in ethanol (50 mL) for 3 days. Removal of solvent gave an oily crude product. Column chromatography on neutral alumina (activity 5) eluting with dichloromethane/methanol (7:3) gave a crude product as solid. Crystallisation from dichloromethane/hexane gave 4.43 g (86%) of colorless crystals, mp 117–119°C; ir: ν/cm\(^{-1}\) 3055 (aryl C-H), 2960 (aliph C-H), 1627 (C=N), 1603 (C=C). NMR data: δ\(_H\) (DMSO-d\(_6\)) 0.91 (3H, m, CH\(_3\)-C\(_4\)H\(_8\)), 1.37 – 1.56 (4H, m, CH\(_3\)-C\(_2\)H\(_2\)-C\(_2\)H\(_4\)), 1.83 (2H, m, C\(_3\)H\(_7\)-CH\(_2\)-CH\(_2\)), 3.41 (2H, m, C\(_4\)H\(_9\)-CH\(_2\)), 6.98 (1H, m, 3-H), 7.43 (1H, m, 7-H), 7.58 (1H, m, 8-H), 7.89 (1H, m, 9-H), 8.16 (1H, m, 2-H). δ\(_C\) (DMSO-d\(_6\)): δ 14.0 (C-5’), 22.1 (C-4’), 25.2 (C-3’), 30.7 (C-2’), 32.2 (C-1’), 106.2 (C-3), 116.3 (C-6), 119.5 (C-9), 121.6 (C-7), 125.8 (C-8), 127.2 (C-5a), 144.3 (C-9a), 151.4 (C-10a), 153.5 (C-4), 155.7 (C-2). MS: m/z (%) = 239 (M\(^+\), 100), 196 (20), 194 (10), 184 (14), 183 (97), 182 (20), 156 (9), 155 (15), 102 (8), 90 (9). Anal. Calcd. for C\(_{15}\)H\(_{17}\)N\(_3\): C, 75.28; H, 7.16; N, 17.56. Found C, 75.10; H, 7.20; N, 17.50.

7,8-Dimethyl-4-pentylpyrimido[1,2-a]benzimidazole (13d). 2-Aminobenzimidazole (1a, 3.23 g, 20 mmol) was refluxed with oct-2-ynal (9b, 2.48 g, 20 mmol) in ethanol (50 mL) for 3 days. Removal of solvent gave a dark brown oil. Purification of this crude product by column chromatography on neutral alumina (activity 5) eluting with hexane/ethyl acetate (1:9) gave a crude solid. Crystallisation from hexane/ethyl acetate gave 3.68 g (68%) of colorless crystals, mp 133–135°C; ir: ν/cm\(^{-1}\) 3075 (aryl C-H), 2957 (aliph.C-H), 1627 (C=N), 1603.
(C=C). NMR data: $\delta_H$ (DMSO-d$_6$): 0.97 (3H, m, CH$_3$-C$_4$H$_8$), 1.39 – 1.61 (4H, m, CH$_3$-C$_2$H$_4$-C$_2$H$_4$), 1.92 (2H, m, C$_3$H$_9$-CH$_2$-CH$_2$), 2.43 (3H, s, 8-CH$_3$), 2.45 (3H, s, 7- CH$_3$), 3.24 (2H, m, C$_4$H$_9$-CH$_2$), 6.60 (1H, s, 3-H), 7.64 (1H, s, 9-H), 7.76 (1H, s, 6-H), 8.56 (1H, m, 2-H). $\delta_C$ (DMSO-d$_6$): 4.1 (C-5'), 20.3 (7-CH$_3$), 20.5 (8-CH$_3$), 22.1 (C-4'), 25.3 (C-3'), 30.8 (C-2'), 32.1 (C-1'), 105.9 (C-3), 115.8 (C-6), 119.3 (C-9), 125.6 (C-5a), 130.6 (C-7), 135.1 (C-8), 143.0 (C-9a), 151.0 (C-10a), 152.9 (C-4), 154.7 (C-2). MS: $m/z$ (%) = 267 (M$^+$, 100), 224 (16), 221 (56), 210 (28), 208 (12), 196 (12), 195 (14), 91 (34), 57 (25), 56 (16), 44 (16), 43 (21), 42 (11), 41 (38), 39 (22). Anal. Calcd. for C$_{17}$H$_{21}$N$_3$: C, 76.37; H, 7.92; N, 15.72. Found C, 76.40; H, 7.94; N, 15.72.

Acknowledgements

The authors are grateful to the University of Yaounde I research grants committee for financial support. They are further grateful to Deutscher Akademischer Austauschdienst (DAAD) for financial support to Helene Wahe (through grant N° 3314 04 003; A/02/18240) and to Fonds der Chemischen Industrie and the administration of the University of Duisburg-Essen for technical and financial assistance.

References

14. Determined by Panlabs, Taiwan. All other new pyrimidobenzimidazoles will be tested in another context.